Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host immune and tissue cells is a broad descriptive term for the various cell types that constitute an organism's body and its defense systems. This category includes immune cells like T-lymphocytes, B-lymphocytes, and macrophages, as well as tissue-specific cells such as hepatocytes, neurons, and myocytes (NIH, 2023). These cells are the sites where therapeutic agents exert their effects, but the term itself does not refer to a specific molecular target like a receptor or enzyme. In the context of drug discovery, specific proteins within these cells are targeted to treat diseases such as cancer, where the goal may be to enhance immune cell activity or inhibit malignant tissue cell growth (Nature Reviews Drug Discovery, 2021). Because this term encompasses a vast array of distinct biological entities and functions, it is considered too non-specific to serve as a defined therapeutic target. Consequently, it is classified as an incorrect target designation for structured pharmacological data.
Not applicable as this is a broad cellular category rather than a specific molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host immune and tissue cells.